Personalized Medicine: A Policy Discussion on the Next Health Frontier

In an era of personalization -- where music apps filter songs based on listener preferences and online ads populated based on user search history -- healthcare is the next frontier. Scientific advances are transforming healthcare and ushering in a new era of personalized – or precision – medicine. This approach makes it possible to account for each patient’s genetics, health history and lifestyle as researchers develop and doctors prescribe individualized treatments. On October 22nd, The Hill convened a discussion on the impact of this emerging field, the challenges to its progress, and how the Precision Medicine Initiative fits into the complex personalized medicine ecosystem.


Featured speakers:

Steven D. Averbuch, M.D., Vice President, Development, Oncology & Pharmacodiagnostics, Bristol-Myers Squibb
Alan Balch, Ph.D., CEO, Patient Advocate Foundation & National Patient Advocate Foundation
John J. Castellani, President & CEO, PhRMA
Kathy Hudson, Ph.D., Deputy Director for Science, Outreach and Policy, National Institutes of Health [NIH]
Elizabeth Mansfield, Ph.D., Director of Personalized Medicine in the Office of In Vitro Diagnos​tics Device Evaluation & Safety, Center for Devices and Radiological Health, Food & Drug Administration [FDA]
Amy Miller, Ph.D., Executive Vice President, Personalized Medicine Coalition

Hosted & moderated by:

Bob Cusack, Editor-in-Chief, The Hill
Sarah Ferris, Staff Writer, The Hill

Share your thoughts with @thehillevents using #PersonalizedMedicine

Sponsored by: